Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans
- Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241
- The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025
- Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former Chair of R&D at GlaxoSmithKline and Khurem Farooq, previously CEO of Aiolos, join Board of Directors
London, UK, 21 November 2024: Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ongoing VXB-241 bivalent RSV-hMPV Phase 1 (P1) study as well as the appointment of Moncef Slaoui, PhD, and Khurem Farooq to its Board of Directors.
